FMP

FMP

Enter

XERS - Xeris Biopharma Holdings, Inc.

Profile of Xeris Biopharma Holdings, Inc.(XERS), Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializi

photo-url-https://financialmodelingprep.com/image-stock/XERS.png

Xeris Biopharma Holdings, Inc.

XERS

NASDAQ

2.21 USD

0.17 (7.69%)

About

ceo

Mr. Paul R. Edick

sector

Healthcare

industry

Biotechnology

website

https://www.xerispharma.com

exchange

NASDAQ

Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

CIK

0001867096

ISIN

US98422E1038

CUSIP

98422E103

Address

180 North LaSalle Street

Phone

844 445 5704

Country

US

Employee

377

IPO Date

Jun 21, 2018

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep